Abstract
In renal cell carcinoma patients with inferior vena cava (IVC) extension, the difficulty of resection increases with the degree of venous extension, which in turn increases the risk of perioperative morbidity and mortality. In addition, the degree of IVC occlusion and associated bland thrombus are reported to be important factors in the choice of operative procedure and in the risk of perioperative complications. Therefore, presurgical treatment to decrease the extent of tumor thrombus would be of significant benefit. Three renal cell carcinoma patients with IVC extension were treated presurgically with axitinib at our institution between September 2012 and November 2013. All patients received axitinib at an initial dose of 5 mg twice daily for 12 weeks. Objective response to treatment was assessed with enhanced computed tomography at 4 and 12 weeks, and therapeutic value was evaluated. Level of inferior vena cava thrombus, according to the classification of Neves et al., and degree of occlusion, according to the classification of Blute et al., were evaluated. Drug-related adverse events and perioperative complications were also investigated. Reduction in primary tumor size was observed in all cases. Two patients showed shortening of tumor thrombus, and a patient with complete occlusion of the IVC by tumor thrombus showed substantial improvement. No grade 3 or greater adverse events and no perioperative complications were observed during treatment. Axitinib may have benefits as a presurgical treatment for renal cell carcinoma patients with IVC extension.
This is a preview of subscription content, log in via an institution to check access.
References
Karnes RJ, Blute ML (2008) Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol 5:329–339
Blute ML, Leibovich BC, Lohse CM et al (2004) The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumor thrombus. BJU Int 94:33–41
Abel EJ, Thompson RH, Margulis V et al (2011) Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience. Eur Urol 59:912–918
Shuch B, Riggs SB, LaRochelle JC et al (2008) Neoadjuvant targeted therapy and advanced kidney cancer: observation and implication for a new treatment paradigm. BJU Int 102:692–696
Karakiewicz PI, Suardi N, Jeldres C et al (2008) Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 53:845–848
Kondo T, Hashimoto Y, Kobayashi H et al (2010) Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical result and histopathological therapeutic effects. Jpn J Clin Oncol 40:1173–1179
Harshman LC, Srinivas S, Kamaya A et al (2009) Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol 6:338–343
Robert G, Gabbay G, Bram R et al (2009) Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol 55:1477–1480
Cost NG, Delacroix SE Jr, Sleeper JP et al (2011) The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 59:912–918
Karam JA, Devine CE, Urbauer DL et al (2014) Phase II trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. doi: 10.1016/j.eururo.2014.01.035 (Epub ahead of print)
Koie T, Ohyama C, Okamoto A et al (2013) Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report. BMC Res Notes 24(6):484
Sassa N, Kato M, Funahashi Y et al (2014) Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma. Jpn J Clin Oncol 44(4):370–373
Rixe O, Bukowski RM, Michaelson MD et al (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975–984
Rini BI, Wilding G, Hudes G et al (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462–4468
Neves RJ, Zinkcke H (1987) Surgical treatment of renal cancer with vena cava extension. Br J Urol 59:390–395
Blute ML, Boorjian SA, Leibovich BC et al (2007) Result of inferior vena cava interruption by Greenfield filter, ligation or resection during radical nephrectomy and thrombectomy. J Urol 178:440–445
Bex A, Van der Veldt AA, Blank C et al (2010) Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol 49(4):520–523
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Mukai, S., Kita, Y., Fujita, N. et al. Presurgical treatment with axitinib in renal cell carcinoma patients with venous extension. Int Canc Conf J 4, 216–220 (2015). https://doi.org/10.1007/s13691-014-0203-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-014-0203-5